Europe's medicines regulator on Friday recommended approving the use of Moderna's COVID-19 vaccine in 12 to 17-year olds, paving the way for it to become the second shot okayed for adolescent use in the bloc.
The use of the vaccine, branded Spikevax, will be the same in adolescents as in people above 18 years, the European Medicines Agency (EMA) said, adding the vaccine produced a comparable antibody response to that seen in 18 to 25-year olds.
Vaccinating children has been considered important for reaching herd immunity against the novel coronavirus and in the light of the highly contagious Delta variant. Moderna in May said its vaccine was found to be safe and effective in teens.
EMA's safety committee said while common side effects in teenagers after vaccination were similar to those seen in older population, due to a smaller study size, the trial could not detect new uncommon side effects or estimate the risk of known ones such as myocarditis and pericarditis.
At least 14 killed in explosion at weapons depot in Syria
US hits five Iranian oil tankers after attack on Navy ships
UK gives air traffic provider a week to probe outage that halted flights
Serbia's President Vucic dissolves parliament, calls snap elections
With large crowds attending, Norway lays King Harald to rest
Jordan intercepts 18 Iranian ballistic missiles
Air traffic control issue disrupts flights at major UK airports
At least 73 injured after Houthi rebels attack Saudi civilian and energy facilities
